SCHEMBL1996845

SCHEMBL1996845

CCn1cnc2c(=O)n(-c3ccc(Cl)cc3)c(N3CCC(c4ccccc4)C3)nc21

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.41
CYP1A2 P05177 2/20 0.41
CYP2C9 P11712 2/20 0.41
CYP2C19 P33261 2/20 0.41
KDM4E B2RXH2 2/20 0.41
TSHR P16473 2/20 0.41
GAA P10253 2/20 0.41
MEN1 O00255 1/20 0.41
CYP3A4 P08684 1/20 0.41
CYP2D6 P10635 1/20 0.41
HPGD P15428 1/20 0.41
MAPK1 P28482 1/20 0.41
KMT2A Q03164 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41
HSD17B10 Q99714 1/20 0.41
MAPT P10636 3/20 0.41
NPC1 O15118 1/20 0.41
RAB9A P51151 1/20 0.41
CNR1 P21554 1/20 0.39
GRM2 Q14416 4/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1989825 0.95 ALDH1A1 (0.44) ALDH1A1CYP1A2CYP2C9CYP2C19KDM4E
SCHEMBL1993933 0.88 ALDH1A1 (0.43) ALDH1A1CYP1A2CYP2C9CYP2C19KDM4E
SCHEMBL1998159 0.84 CNR2 (0.38) ALDH1A1CYP1A2CYP2C9CYP2C19KDM4E
SCHEMBL1993439 0.84 ALDH1A1 (0.42) ALDH1A1CYP1A2CYP2C9CYP2C19KDM4E
SCHEMBL2000177 0.83 ALDH1A1 (0.44) ALDH1A1CYP1A2CYP2C9CYP2C19KDM4E
SCHEMBL1997995 0.82 ALDH1A1 (0.48) ALDH1A1CYP1A2CYP2C9CYP2C19KDM4E
SCHEMBL1991529 0.81 KDM4E (0.38) ALDH1A1CYP1A2CYP2C9CYP2C19KDM4E
SCHEMBL1990704 0.81 KDM4E (0.38) ALDH1A1CYP1A2CYP2C9CYP2C19KDM4E
SCHEMBL1994026 0.80 ALDH1A1 (0.45) ALDH1A1CYP1A2CYP2C9CYP2C19KDM4E
SCHEMBL1994613 0.79 MAP4K4 (0.42) ALDH1A1CYP1A2CYP2C9CYP2C19KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1866310-B1 2,3-SUBSTITUTED FUSED PYRIMIDIN-4(3H)-ONES AS VR1 ANTAGONISTS MERCK SHARP & DOHME (GB) 2012-07-11 EP disclosed
US-20110152242-A1 2,3-Substituted Fused Pyrimidin -4 (3H)-Ones as VR1 Antagonists MERCK SHARP & DOHME LTD. (GB) 2011-06-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110152242-A1 2,3-Substituted Fused Pyrimidin -4 (3H)-Ones as VR1 Antagonists NR2C2, NR3C2, NR2E3 ALDH1A1 1796/4885CYP1A2 608/4885CYP2C9 788/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.